Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients.
Si-Yang LiuHao SunJia-Ying ZhouGuang-Ling JieZhi XieYang ShaoXian ZhangJun-Yi YeChun-Xiang ChenXu-Chao ZhangQing ZhouJin-Ji YangYi-Long WuPublished in: Biomarker research (2020)
In the largest sample used thus for, our study found that approximately 10% of Chinese NSCLC patients had KRAS mutations. Of these, nearly 30% harbored the KRAS G12C mutation subtype, which was most common in male smokers. The KRAS G12C mutation is a biomarker of poor prognosis in Chinese NSCLC patients, which could potentially be improved by G12C-specific inhibitors in the future.(296 words).